Literature DB >> 23205615

Ciprofloxacin shows synergism with classical antifungals against Histoplasma capsulatum var. capsulatum and Coccidioides posadasii.

R S N Brilhante1, E P Caetano, J J C Sidrim, R A Cordeiro, Z P Camargo, M A B Fechine, R A C Lima, D S C M Castelo Branco, F J F Marques, J R L Mesquita, D T Lima, A J Monteiro, M F G Rocha.   

Abstract

This study evaluated the in vitro interaction between ciprofloxacin (CIP) and classical antifungals against Histoplasma capsulatum var. capsulatum in mycelial (n = 16) and yeast-like forms (n = 9) and Coccidioides posadasii in mycelial form (n = 16). This research was conducted through broth microdilution and macrodilution, according to Clinical Laboratory Standards Institute. Inocula were prepared to obtain from 0.5 × 10(3) to 2.5 × 10(4)  cfu ml(-1) for H. capsulatum and from 10(3) to 5 × 10(3)  cfu ml(-1) for C. posadasii. Initially, minimum inhibitory concentration (MIC) for each drug alone was determined. Then, these MICs were used as the highest concentration for each drug during combination assays. The procedures were performed in duplicate. For all combination assays, MICs were defined as the lowest concentration capable of inhibiting 80% of visible fungal growth, when compared to the drug-free control. Drug interaction was evaluated by paired sample t-Student test. The obtained data showed a significant MIC reduction for most tested combinations of CIP with antifungals, except for that of CIP and voriconazole against yeast-like H. capsulatum. This study brings potential alternatives for the treatment of histoplasmosis and coccidioidomycosis, raising the possibility of using CIP as an adjuvant antifungal therapy, providing perspectives to delineate in vivo studies.
© 2012 Blackwell Verlag GmbH.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23205615     DOI: 10.1111/myc.12025

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  7 in total

1.  Antifungal therapeutics for dimorphic fungal pathogens.

Authors:  Kristie D Goughenour; Chad A Rappleye
Journal:  Virulence       Date:  2016-09-19       Impact factor: 5.882

2.  Endemic mycoses in immunocompromised hosts.

Authors:  Trent R Malcolm; Peter V Chin-Hong
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

Review 3.  Progressive disseminated histoplasmosis in the HIV population in Europe in the HAART era. Case report and literature review.

Authors:  R Martin-Iguacel; J Kurtzhals; G Jouvion; S D Nielsen; J M Llibre
Journal:  Infection       Date:  2014-03-14       Impact factor: 3.553

4.  A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents.

Authors:  Tim R Blower; Afif Bandak; Amy S Y Lee; Caroline A Austin; John L Nitiss; James M Berger
Journal:  Nucleic Acids Res       Date:  2019-09-05       Impact factor: 16.971

Review 5.  Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?

Authors:  A Dalhoff
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-12-17       Impact factor: 3.267

6.  Metrics of Antifungal Effects of Ciprofloxacin on Aspergillus fumigatus Planktonic Growth and Biofilm Metabolism; Effects of Iron and Siderophores.

Authors:  Gabriele Sass; Lynn Scherpe; Marife Martinez; Julianne J Marsh; David A Stevens
Journal:  J Fungi (Basel)       Date:  2022-02-28

7.  Terpinen-4-ol, tyrosol, and β-lapachone as potential antifungals against dimorphic fungi.

Authors:  Raimunda Sâmia Nogueira Brilhante; Érica Pacheco Caetano; Rita Amanda Chaves de Lima; Francisca Jakelyne de Farias Marques; Débora de Souza Collares Maia Castelo-Branco; Charlline Vládia Silva de Melo; Glaucia Morgana de Melo Guedes; Jonathas Sales de Oliveira; Zoilo Pires de Camargo; José Luciano Bezerra Moreira; André Jalles Monteiro; Tereza de Jesus Pinheiro Gomes Bandeira; Rossana de Aguiar Cordeiro; Marcos Fábio Gadelha Rocha; José Júlio Costa Sidrim
Journal:  Braz J Microbiol       Date:  2016-07-26       Impact factor: 2.214

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.